Anders Martin-Löf
Director of Finance/CFO bei BIOARCTIC AB
Vermögen: 16 320 $ am 31.03.2024
Profil
Mr. Anders Martin-Löf is a Chief Financial Officer & Secretary at BioArctic AB and an Independent Director at Cantargia AB.
He is on the Board of Directors at Cantargia AB, Affibody Medical AB, Lisa Martin-Löf Konsultbyrå AB and Oncopeptides Incentive AB.
Mr. Martin-Löf was previously employed as a Chief Financial Officer & Deputy CEO by Oncopeptides AB, a Chief Financial Officer by Wilson Therapeutics AB, a CFO, Investor Relations & Press Contact by RaySearch Laboratories AB, a Chief Financial Officer by A3P Biomedical AB, a Director-Investor Relations by Biovitrum AB, a Chief Financial Officer by Extenda AB, and a Head-Investor Relations by Swedish Orphan Biovitrum AB.
He also served on the board at Sciencecap Stockholm AB.
He received his undergraduate degree from the University of Stockholm, a graduate degree from Royal Institute of Technology and a graduate degree from ENSIMAG.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CANTARGIA AB
0,03% | 31.12.2022 | 50 000 ( 0,03% ) | 16 320 $ | 31.03.2024 |
Aktive Positionen von Anders Martin-Löf
| Unternehmen | Position | Beginn |
|---|---|---|
| CANTARGIA AB | Director/Board Member | 01.01.2018 |
| BIOARCTIC AB | Director of Finance/CFO | 01.06.2023 |
| Lisa Martin-Löf Konsultbyrå AB | Director/Board Member | - |
| Oncopeptides Incentive AB | Director/Board Member | - |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Director/Board Member | - |
Ehemalige bekannte Positionen von Anders Martin-Löf
| Unternehmen | Position | Ende |
|---|---|---|
| ONCOPEPTIDES AB | Director of Finance/CFO | 08.11.2021 |
| RAYSEARCH LABORATORIES AB | Director of Finance/CFO | 02.07.2015 |
A3P Biomedical AB
 A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Director of Finance/CFO | - |
| SWEDISH ORPHAN BIOVITRUM AB | Investor Relations Contact | - |
| ░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - |
Ausbildung von Anders Martin-Löf
| University of Stockholm | Undergraduate Degree |
| Royal Institute of Technology | Graduate Degree |
| ENSIMAG | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| RAYSEARCH LABORATORIES AB | Technology Services |
| ONCOPEPTIDES AB | Health Technology |
| BIOARCTIC AB | Health Technology |
| CANTARGIA AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Extenda AB
 Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Technology Services |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
| Oncopeptides Incentive AB | |
| Sciencecap Stockholm AB | |
| Lisa Martin-Löf Konsultbyrå AB | |
A3P Biomedical AB
A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Health Services |
